DE69130166T2 - Verfahren und zusammensetzungen zur synthese von bch-189 und verwandten verbindungen - Google Patents

Verfahren und zusammensetzungen zur synthese von bch-189 und verwandten verbindungen

Info

Publication number
DE69130166T2
DE69130166T2 DE69130166T DE69130166T DE69130166T2 DE 69130166 T2 DE69130166 T2 DE 69130166T2 DE 69130166 T DE69130166 T DE 69130166T DE 69130166 T DE69130166 T DE 69130166T DE 69130166 T2 DE69130166 T2 DE 69130166T2
Authority
DE
Germany
Prior art keywords
bch
related compounds
synthesising
compositions
analogues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69130166T
Other languages
English (en)
Other versions
DE69130166T3 (de
DE69130166D1 (de
Inventor
Dennis Liotta
Woo-Baeg Choi
Raymond F Schinazi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23879071&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69130166(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Emory University filed Critical Emory University
Application granted granted Critical
Publication of DE69130166D1 publication Critical patent/DE69130166D1/de
Publication of DE69130166T2 publication Critical patent/DE69130166T2/de
Publication of DE69130166T3 publication Critical patent/DE69130166T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
DE69130166T 1990-02-01 1991-01-31 Verfahren und zusammensetzungen zur synthese von bch-189 und verwandten verbindungen Expired - Lifetime DE69130166T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/473,318 US5204466A (en) 1990-02-01 1990-02-01 Method and compositions for the synthesis of bch-189 and related compounds
US473318 1990-02-01
PCT/US1991/000685 WO1991011186A1 (en) 1990-02-01 1991-01-31 Method and compositions for the synthesis of bch-189 and related compounds

Publications (3)

Publication Number Publication Date
DE69130166D1 DE69130166D1 (de) 1998-10-15
DE69130166T2 true DE69130166T2 (de) 1999-04-08
DE69130166T3 DE69130166T3 (de) 2005-04-14

Family

ID=23879071

Family Applications (4)

Application Number Title Priority Date Filing Date
DE200412000015 Active DE122004000015I2 (de) 1990-02-01 1991-01-31 Verfahren und zusammensetzungen zur Synthese von BCH-189 und verwandten Verbindungen.
DE69133556T Expired - Lifetime DE69133556T2 (de) 1990-02-01 1991-01-31 Verfahren und Zusammensetzungen für die Synthese von BCH-189 und verwandten Verbindungen
DE0513200T Pending DE513200T1 (de) 1990-02-01 1991-01-31 Verfahren und zusammensetzungen zur synthese von bch-189 und verwandten verbindungen.
DE69130166T Expired - Lifetime DE69130166T3 (de) 1990-02-01 1991-01-31 Verfahren und zusammensetzungen zur synthese von bch-189 und verwandten verbindungen

Family Applications Before (3)

Application Number Title Priority Date Filing Date
DE200412000015 Active DE122004000015I2 (de) 1990-02-01 1991-01-31 Verfahren und zusammensetzungen zur Synthese von BCH-189 und verwandten Verbindungen.
DE69133556T Expired - Lifetime DE69133556T2 (de) 1990-02-01 1991-01-31 Verfahren und Zusammensetzungen für die Synthese von BCH-189 und verwandten Verbindungen
DE0513200T Pending DE513200T1 (de) 1990-02-01 1991-01-31 Verfahren und zusammensetzungen zur synthese von bch-189 und verwandten verbindungen.

Country Status (22)

Country Link
US (8) US5204466A (de)
EP (3) EP0872237B1 (de)
JP (6) JPH07618B2 (de)
KR (2) KR100381705B1 (de)
AT (1) ATE170750T1 (de)
AU (6) AU658136C (de)
BG (1) BG62236B1 (de)
CA (3) CA2678778A1 (de)
DE (4) DE122004000015I2 (de)
DK (2) DK0513200T4 (de)
ES (2) ES2279559T3 (de)
FI (4) FI114471B (de)
GR (1) GR950300024T1 (de)
HK (1) HK1014664A1 (de)
HU (4) HU227485B1 (de)
LU (1) LU91073I2 (de)
MC (1) MC2233A1 (de)
NL (1) NL300148I2 (de)
NO (6) NO923014D0 (de)
RO (1) RO108564B1 (de)
RU (1) RU2125558C1 (de)
WO (1) WO1991011186A1 (de)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
US5684164A (en) * 1988-04-11 1997-11-04 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US6350753B1 (en) 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
ES2196004T3 (es) * 1989-02-08 2003-12-16 Iaf Biochem Int Procedimiento para preparar 1,3-oxatiolanos sustituidos con propiedades antivirales.
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US20090239887A1 (en) * 1990-02-01 2009-09-24 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US6703396B1 (en) * 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US6346627B1 (en) * 1990-02-01 2002-02-12 Emory University Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
IL100965A (en) * 1991-02-22 1999-12-31 Univ Emory 2 - Hydroxymethyl - 5 -) 5 - Fluorocytocin - 1 - Eyal (- 1, 3 - Oxathiolane, its resolution and pharmaceuticals containing it
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
ATE361293T1 (de) * 1991-03-06 2007-05-15 Univ Emory Salze und amide von (-) cis 5-fluoro-2'-deoxy-3'- thiacytidine geeignet für die behandlung von hepatitis b
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9109506D0 (en) * 1991-05-02 1991-06-26 Wellcome Found Therapeutic nucleosides
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923641B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US20050192299A1 (en) * 1992-04-16 2005-09-01 Yung-Chi Cheng Method of treating or preventing hepatitis B virus
GB9311709D0 (en) * 1993-06-07 1993-07-21 Iaf Biochem Int Stereoselective synthesis of nucleoside analogues using bicycle intermediate
AU7954694A (en) 1993-09-10 1995-03-27 Centre National De La Recherche Scientifique (Cnrs) Nucleosides with anti-hepatitis b virus activity
US20020120130A1 (en) * 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US6689761B1 (en) 1995-02-01 2004-02-10 Merck & Co., Inc. Combination therapy for HIV infection
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
GB9506644D0 (en) * 1995-03-31 1995-05-24 Wellcome Found Preparation of nucleoside analogues
DE19514523A1 (de) * 1995-04-12 1996-10-17 Schering Ag Neue Cytosin- und Cytidinderivate
ES2276404T3 (es) * 1995-06-07 2007-06-16 Emory University Nucleosidos con actividad antivirus de la hepatitis-b.
CZ429498A3 (cs) 1996-06-25 1999-06-16 Glaxo Group Limited Kombinace obsahující VX478, zidovudin, FTC a/nebo 3TC pro léčbu infekce HIV
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
US5792773A (en) * 1996-11-15 1998-08-11 Yale University L-β-dioxolane uridine analog administration for treating Epstein-Barr virus infection
EA001920B1 (ru) 1997-03-19 2001-10-22 Эмори Юниверсити Синтез 1,3-оксаселеноланнуклеозидов, их активность против вируса иммунодефицита человека и против вируса гепатита-b
AU6898498A (en) 1997-04-07 1998-10-30 Triangle Pharmaceuticals, Inc. Use of mkc-442 in combination with other antiviral agents
EP1754710A3 (de) 1998-02-25 2007-12-19 Emory University 2'-Fluoronukleoside
CA2322008C (en) 1998-02-25 2011-06-28 Emory University 2'-fluoronucleosides
DE122007000062I1 (de) * 1998-08-10 2007-12-20 Idenix Cayman Ltd Beta-L-2'-deoxynukleoside für die Behandlung von Hepatitis-B-Virus
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
CA2714085C (en) * 1998-08-12 2013-02-05 Emory University Method of manufacture of 1,3-oxathiolane nucleosides
US6979561B1 (en) * 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
EP1124562B1 (de) 1998-11-02 2005-01-19 Gilead Sciences, Inc. Kombinationstherapie zur behandlung von hepatitis b infektionen
US6407077B1 (en) 1998-11-05 2002-06-18 Emory University β-L nucleosides for the treatment of HIV infection
US6458773B1 (en) 1998-11-05 2002-10-01 Emory University Nucleoside with anti-hepatitis B virus activity
NZ513094A (en) 1998-12-23 2004-05-28 Shire Biochem Inc Antiviral nucleoside analogues
US7205404B1 (en) 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
US6653318B1 (en) 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
TR200601784T2 (tr) * 1999-11-12 2007-01-22 Pharmasset Ltd. 2'-deoksi-L-nükleositlerin sentezi
EP1634888A3 (de) 1999-11-12 2007-11-21 Pharmasset, Inc. Synthese von 2'-Deoxy-L-Nukleosiden
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
CA2308559C (en) 2000-05-16 2005-07-26 Brantford Chemicals Inc. 1,3-oxathiolan-5-ones useful in the production of antiviral nucleoside analogues
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1736478B1 (de) * 2000-05-26 2015-07-22 IDENIX Pharmaceuticals, Inc. Verfahren und Zusammensetzungen zur Behandlung von Flaviviren und Pestiviren
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
US6875751B2 (en) * 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
EP1311524A2 (de) * 2000-08-09 2003-05-21 Kolon Industries, Inc. 5'-deoxy-n-(substituiertes oxycarbonyl)-5-fluorocytosin und derivate davon, verfahren zur herstellung derselben und eine anti-krebs-zusammensetzungmit denselben als aktive ingredentien
US20030166606A1 (en) * 2000-08-09 2003-09-04 Kwan-Hee Kim 5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients
US20030228320A1 (en) * 2000-08-18 2003-12-11 Ashdown Martin Leonard Retroviral immunotherapy
CN101862345B (zh) 2000-10-18 2014-06-04 吉利德制药有限责任公司 用于治疗病毒感染和异常细胞增殖的修饰核苷类化合物
DE10104231A1 (de) * 2001-01-31 2002-08-08 Consortium Elektrochem Ind Verfahren zur enzymatischen Herstellung von enantiomerenreinen 1,3-Dioxolan-4-on-Derivaten
ATE312097T1 (de) * 2001-03-01 2005-12-15 Gilead Sciences Inc Polymorphe und andere kristalline formen von cis- ftc
US6858721B2 (en) * 2001-05-01 2005-02-22 Mitsui Chemicals, Inc. Method for producing cytosine nucleoside compounds
CA2351049C (en) 2001-06-18 2007-03-13 Brantford Chemicals Inc. Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers
ITMI20012317A1 (it) * 2001-11-06 2003-05-06 Recordati Ind Chimica E Farma Processo diastereoselettivo per la preparazione del'agente antivirale4-amino-1-(2r-idrossimetil-/1,3/ossatiolan-5s-i1)-1h-pirimidin-2-one
BR0214940A (pt) * 2001-12-14 2006-05-30 Pharmasset Ltd preparação de intermediários úteis na sìntese de nucleosìdeos antivirais
AUPS054702A0 (en) * 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
CN1329407C (zh) * 2002-04-12 2007-08-01 阿奇林医药品公司 合成β－L－5－氟－2′,3′－双脱氧－2′,3′－双脱氢胞嘧啶核苷的方法
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
AP2005003213A0 (en) * 2002-06-28 2005-03-31 Univ Cagliari 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections.
CN101172993A (zh) * 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
KR101108115B1 (ko) 2002-08-06 2012-01-31 파마셋 인코포레이티드 1,3-디옥솔란 뉴클레오사이드의 제조 방법
TWI244393B (en) * 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
JP4173861B2 (ja) * 2002-09-13 2008-10-29 イデニクス（ケイマン）リミテツド 耐性ＨＢＶ菌株の治療のためのβ−Ｌ−２’−デオキシヌクレオシド及び併用療法
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
CA2502625A1 (en) * 2002-12-09 2004-06-24 The University Of Georgia Research Foundation, Inc. Dioxolane thymine and combinations for use against resistant strains of hiv
CA2509687C (en) * 2002-12-12 2012-08-14 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
CA2512319A1 (en) * 2003-01-14 2004-08-05 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
AU2004224191A1 (en) 2003-03-24 2004-10-07 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
ITMI20030578A1 (it) * 2003-03-24 2004-09-25 Clariant Lsm Italia Spa Processo ed intermedi per la preparazione di emtricitabina
EP1639121A4 (de) * 2003-06-30 2008-04-16 Idenix Cayman Ltd Synthese von beta-l-2-desoxynukleosiden
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
DE602004030369D1 (de) 2003-10-24 2011-01-13 Immunaid Pty Ltd Therapieverfahren
BRPI0507363A (pt) * 2004-02-03 2007-07-03 Univ Emory métodos para manufatura de 1,3-dioxolano nucleosìdeos
DK1778251T3 (da) 2004-07-27 2011-07-18 Gilead Sciences Inc Nukleosidphosphatkonjugater som anti-HIV-midler
JP4058057B2 (ja) * 2005-04-26 2008-03-05 株式会社東芝 日中機械翻訳装置、日中機械翻訳方法および日中機械翻訳プログラム
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
KR20080056220A (ko) 2005-10-19 2008-06-20 에프. 호프만-라 로슈 아게 페닐-아세트아마이드 ｎｎｒｔ 저해제
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
CA2634749C (en) * 2005-12-23 2014-08-19 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
DE602007005349D1 (de) * 2006-01-17 2010-04-29 Organon Nv SELEKTIVE ENZYMATISCHE HYDROLYSE VON C-TERMINALEN tert-BUTYL-PEPTIDESTERN
US9044509B2 (en) 2006-02-03 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibition of HIV infection through chemoprophylaxis
US8895531B2 (en) * 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
AU2007237818B2 (en) * 2006-04-18 2012-09-27 Lupin Limited A novel crystalline form of lamivudine
RS54237B9 (sr) 2006-07-07 2019-07-31 Gilead Sciences Inc Modulatori farmakokinetičkih svojstava terapeutika
JP5415957B2 (ja) 2006-12-13 2014-02-12 エフ．ホフマン−ラ ロシュ アーゲー 非ヌクレオシド逆転写酵素阻害剤としての２−（ピペリジン−４−イル）−４−フェノキシ−又はフェニルアミノ−ピリミジン誘導体
PL3150586T3 (pl) 2007-02-23 2020-06-01 Gilead Sciences, Inc. Modulatory farmakokinetycznych właściwości środków terapeutycznych
CN101307048B (zh) * 2007-05-18 2011-03-23 上海迪赛诺医药发展有限公司 立体选择性制备拉米夫定的方法
WO2008154817A1 (fr) 2007-06-18 2008-12-24 Zhang, Zhongneng Thiazolyl-dihydropyrimidines à substitution bromo-phényle
US9296776B2 (en) 2007-07-09 2016-03-29 Eastern Virginia Medical School Substituted nucleoside derivatives with antiviral and antimicrobial properties
WO2009052050A1 (en) * 2007-10-15 2009-04-23 Pharmasset, Inc. Dioxolane thymine phosphoramidates as anti-hiv agents
SI2225232T1 (sl) * 2007-11-29 2012-12-31 Ranbaxy Laboratories Limited Postopek za pripravo substituiranih 1,3-oksatiolanov
AU2008331167A1 (en) * 2007-11-29 2009-06-04 Ranbaxy Laboratories Limited Process and intermediates for the preparation of substituted 1, 3-oxathiolanes, especially lamivudine
JPWO2009107692A1 (ja) 2008-02-29 2011-07-07 株式会社カネカ ２’−水酸基が保護されたリボヌクレオシド誘導体およびその製造方法
EP2350065A1 (de) * 2008-11-12 2011-08-03 Lupin Ltd. Neues polymorph von emtricitabin und verfahren zu dessen herstellung
PL2364314T3 (pl) 2008-12-09 2014-08-29 Gilead Sciences Inc Modulatory receptorów Toll-podobnych
WO2010082128A1 (en) 2009-01-19 2010-07-22 Aurobindo Pharma Limited Process for the preparation of cis-nucleoside derivative
KR101474570B1 (ko) 2009-04-13 2014-12-19 주식회사 대희화학 라미부딘의 신규한 중간체 및 이의 제조방법
EP2982978A1 (de) 2009-05-27 2016-02-10 Immunaid Pty Ltd Verfahren zur behandlung von krankheiten
US8710218B2 (en) 2009-07-15 2014-04-29 Lupin Limited Process for preparation of Efavirenz
WO2011095987A1 (en) 2010-02-03 2011-08-11 Matrix Laboratories Ltd. Novel process for the preparation of cis-nucleoside derivative
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
WO2011141805A2 (en) 2010-05-14 2011-11-17 Lupin Limited An improved process for the manufacture of lamivudine
US20130296562A1 (en) 2011-08-05 2013-11-07 Lupin Limited Stereoselective process for preparation of 1,3-oxathiolane nucleosides
CN102584800A (zh) * 2011-12-16 2012-07-18 四川大学 手性吲哚酮和当归内酯骨架化合物及不对称合成
AU2013257951A1 (en) 2012-05-11 2015-01-22 Akron Molecules Ag Use of compounds for the treatment of pain
HUE044605T2 (hu) * 2012-11-16 2019-11-28 Univ College Cardiff Consultants Ltd RP/SP gemcitabin-[fenil-(benziloxi-L-alaninil)]-foszfát keveréke
SI3608325T1 (sl) 2012-12-21 2022-09-30 Gilead Sciences, Inc. Policiklične-karbamoilpiridonske spojine in njihova farmacevtska uporaba
WO2015006731A1 (en) 2013-07-12 2015-01-15 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections
NO2865735T3 (de) 2013-07-12 2018-07-21
MX2016002560A (es) 2013-08-29 2016-10-26 Teva Pharma Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir.
EP3623364A1 (de) 2014-02-13 2020-03-18 Ligand Pharmaceuticals, Inc. Organische verbindungen und deren verwendungen
AU2015245217A1 (en) 2014-04-08 2016-10-13 Teva Pharmaceutical Industries Ltd. Unit dosage form comprising Emtricitabine, Tenofovir, Darunavir and Ritonavir
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (de) 2014-06-20 2018-06-23
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
JP2017520545A (ja) 2014-07-02 2017-07-27 リガンド・ファーマシューティカルズ・インコーポレイテッド プロドラッグ化合物およびそれらの使用
AU2015287773B2 (en) 2014-07-11 2018-03-29 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of HIV
US9675632B2 (en) 2014-08-26 2017-06-13 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
ES2837383T3 (es) 2015-04-02 2021-06-30 Gilead Sciences Inc Compuestos de carbamoilpiridonas policíclicos y su utilización farmacéutica
MA42818A (fr) 2015-09-15 2018-07-25 Gilead Sciences Inc Modulateurs de récepteurs de type toll pour le traitement du vih
GB201610327D0 (en) * 2016-06-14 2016-07-27 Univ Nelson Mandela Metropolitan Process for producing Lamivudine and Entricitabine
WO2018178722A1 (en) * 2017-03-31 2018-10-04 The University Of Liverpool Prodrug compositions

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000137A (en) * 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
JPS5259171A (en) * 1975-11-10 1977-05-16 Asahi Chem Ind Co Ltd Preparation of uracil derivatives
JPS6045196B2 (ja) * 1976-08-09 1985-10-08 株式会社興人 １−（２−テトラヒドロフリル）ウラシル類の製造方法
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
JPS5738774A (en) * 1980-08-19 1982-03-03 Chugai Pharmaceut Co Ltd Uracil derivative and its preparation
JPS5839672A (ja) * 1981-09-03 1983-03-08 Chugai Pharmaceut Co Ltd ウラシル誘導体
DE3481191D1 (de) * 1983-07-20 1990-03-08 Teijin Ltd Antineoplastisches mittel.
DE3534979A1 (de) * 1985-07-25 1987-01-29 Licentia Gmbh Netzgeraet
JPS62501712A (ja) * 1985-08-26 1987-07-09 アメリカ合衆国 ２′、３′―ジデオキシイノシン、２′，３′―ジデオキシグアノシンまたは２′，３′―ジデオキシアデノシンを含有する抗ｈｔｌｖ―３／ｌａｖ剤
US4879277A (en) * 1985-08-26 1989-11-07 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions and methods
GB2181128A (en) * 1985-09-17 1987-04-15 Wellcome Found 3'-azidonucleosides
US4916122A (en) * 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
US4963533A (en) * 1986-10-24 1990-10-16 Stichting Rega Vzw (Rega) Therapeutic application of dideoxycytidinene
EP0342203B1 (de) * 1987-03-24 1994-07-06 Nycomed Imaging As 2',3'-dideoxyribofuranoxid-derivate
US5185437A (en) * 1987-04-09 1993-02-09 Burroughs Wellcome Co. Therapeutic nucleosides
US5011774A (en) * 1987-07-17 1991-04-30 Bristol-Myers Squibb Co. Dideoxyinosine by enzymatic deamination of dideoxyadenosine
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5684164A (en) * 1988-04-11 1997-11-04 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US4900828A (en) * 1988-05-12 1990-02-13 Hoffmann-Laroche Inc. Intermediate compounds and an improved procedure for the synthesis of 2',3'-dideoxycytidine
CA1318627C (en) * 1988-07-14 1993-06-01 Jeffrey M. Howell Enzymatic resolution process
US5106750A (en) * 1988-08-30 1992-04-21 G. D. Searle & Co. Enantio- and regioselective synthesis of organic compounds using enol esters as irreversible transacylation reagents
JPH0269476A (ja) * 1988-09-06 1990-03-08 Kohjin Co Ltd ピリミジン誘導体の製法
JPH0269469A (ja) * 1988-09-06 1990-03-08 Kohjin Co Ltd ジヒドロフラン誘導体及びその製法
GB8822546D0 (en) * 1988-09-26 1988-11-02 Wellcome Found Antiviral combinations
CA2005815C (en) * 1988-12-19 1999-08-03 Wellcome Foundation Limited (The) Antiviral acyclic nucleoside derivatives
ES2196004T3 (es) * 1989-02-08 2003-12-16 Iaf Biochem Int Procedimiento para preparar 1,3-oxatiolanos sustituidos con propiedades antivirales.
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
US5059690A (en) * 1990-03-01 1991-10-22 E. R. Squibb & Sons, Inc. Purinyl tetrahydrofurans
CA2023856A1 (en) * 1989-09-26 1991-03-27 Jeffrey M. Howell Enzymatic resolution process
US5071983A (en) * 1989-10-06 1991-12-10 Burroughs Wellcome Co. Therapeutic nucleosides
IE904378A1 (en) * 1989-12-20 1991-07-03 Abbott Lab Analogs of oxetanyl purines and pyrimidines
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US6703396B1 (en) * 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5700937A (en) * 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6346627B1 (en) * 1990-02-01 2002-02-12 Emory University Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
IT1246983B (it) * 1990-11-13 1994-12-12 Consiglio Nazionale Ricerche L-2'-desossiuridine e composizioni farmaceutiche che le contengono.
US5587480A (en) * 1990-11-13 1996-12-24 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
WO1992010496A1 (en) * 1990-12-05 1992-06-25 University Of Georgia Research Foundation, Inc. ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
IL100965A (en) * 1991-02-22 1999-12-31 Univ Emory 2 - Hydroxymethyl - 5 -) 5 - Fluorocytocin - 1 - Eyal (- 1, 3 - Oxathiolane, its resolution and pharmaceuticals containing it
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
ATE361293T1 (de) * 1991-03-06 2007-05-15 Univ Emory Salze und amide von (-) cis 5-fluoro-2'-deoxy-3'- thiacytidine geeignet für die behandlung von hepatitis b
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923641B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
GB9307013D0 (en) * 1993-04-02 1993-05-26 Wellcome Found Therapeutic combinations
SE510803C2 (sv) * 1994-12-13 1999-06-28 Volvo Ab Tryckmediepåverkad manöveranordning
US5639787A (en) * 1995-02-28 1997-06-17 The Center For The Improvement Of Human Functioning Int'l, Inc. Therapeutic method for the treatment of cancer

Also Published As

Publication number Publication date
NO970385L (no) 1992-07-30
AU2010201878A1 (en) 2010-05-27
FI121069B (fi) 2010-06-30
NO20065640L (no) 1992-07-30
DE69133556D1 (de) 2007-03-08
NL300148I2 (nl) 2004-11-01
KR920703582A (ko) 1992-12-18
FI20030933A (fi) 2003-06-24
DE69130166T3 (de) 2005-04-14
JPH07618B2 (ja) 1995-01-11
DK0872237T3 (da) 2007-04-23
GR950300024T1 (en) 1995-06-30
CA2075189A1 (en) 1991-08-02
US5204466A (en) 1993-04-20
NL300148I1 (nl) 2004-07-01
NO970385D0 (no) 1997-01-29
HU211300A9 (en) 1995-11-28
BG62236B1 (bg) 1999-06-30
NO313048B1 (no) 2002-08-05
NO20083728L (no) 1992-07-30
RO108564B1 (ro) 1994-06-30
EP0513200B1 (de) 1998-09-09
DK0513200T4 (da) 2004-07-05
DE122004000015I2 (de) 2004-11-18
AU658136B2 (en) 1995-04-06
ATE170750T1 (de) 1998-09-15
DE69133556T2 (de) 2007-08-16
AU4031995A (en) 1996-04-26
FI20060622A (fi) 2006-06-27
JP2006141408A (ja) 2006-06-08
NO326249B1 (no) 2008-10-27
AU2006207874A1 (en) 2006-09-28
AU698859C (en) 2003-01-30
ES2076130T1 (es) 1995-11-01
AU2006207874B2 (en) 2010-02-11
KR100381705B1 (ko) 2003-04-26
JP3844978B2 (ja) 2006-11-15
AU4474599A (en) 1999-11-11
NO2008011I1 (no) 2008-07-28
CA2075189C (en) 2004-11-30
FI114471B (fi) 2004-10-29
US20050004148A1 (en) 2005-01-06
FI20050672A (fi) 2005-06-22
MC2233A1 (fr) 1993-02-23
KR100188357B1 (ko) 1999-06-01
FI923446A0 (fi) 1992-07-30
EP1772151A2 (de) 2007-04-11
ES2279559T3 (es) 2007-08-16
US5814639A (en) 1998-09-29
NO970386D0 (no) 1997-01-29
JP2002012591A (ja) 2002-01-15
CA2481078A1 (en) 1991-08-08
LU91073I2 (fr) 2004-04-23
ES2076130T3 (es) 1999-03-01
NO923014L (no) 1992-07-30
NO2008011I2 (no) 2010-10-18
DK0513200T3 (da) 1999-05-25
US5914400A (en) 1999-06-22
US6153751A (en) 2000-11-28
FI923446A (fi) 1992-07-30
DE69130166D1 (de) 1998-10-15
FI116222B (fi) 2005-10-14
JP2001019690A (ja) 2001-01-23
EP0513200A1 (de) 1992-11-19
CA2481078C (en) 2009-12-15
JP4496377B2 (ja) 2010-07-07
DE513200T1 (de) 1995-07-13
HU9202496D0 (en) 1992-12-28
HK1014664A1 (en) 1999-09-30
JP4108645B2 (ja) 2008-06-25
JP2005053893A (ja) 2005-03-03
EP0872237A1 (de) 1998-10-21
JP2001352997A (ja) 2001-12-25
AU7300491A (en) 1991-08-21
AU698859B2 (en) 1998-11-12
HU227485B1 (en) 2011-07-28
NO923014D0 (no) 1992-07-30
AU658136C (en) 2003-06-12
ES2076130T5 (es) 2004-12-16
RU2125558C1 (ru) 1999-01-27
US6114343A (en) 2000-09-05
JP3530150B2 (ja) 2004-05-24
EP0513200B2 (de) 2004-04-28
EP1772151A3 (de) 2007-06-13
WO1991011186A1 (en) 1991-08-08
HUT62566A (en) 1993-05-28
EP0513200A4 (en) 1993-04-07
AU2002300661B2 (en) 2006-06-08
NO970386L (no) 1992-07-30
NO324979B1 (no) 2008-01-14
EP0872237B1 (de) 2007-01-17
CA2678778A1 (en) 1991-08-08
JPH05505794A (ja) 1993-08-26
US5539116A (en) 1996-07-23
US5210085A (en) 1993-05-11
DE122004000015I1 (de) 2004-08-12

Similar Documents

Publication Publication Date Title
DE69130166D1 (de) Verfahren und zusammensetzungen zur synthese von bch-189 und verwandten verbindungen
ES2174387T3 (es) Compuestos de 5-halo-5-desoxi-sorbopiranosa.